Dr. Preethi John, MD
What this data tells you about Dr. John
Dr. Preethi John is a medical oncology specialist in Dallas, TX, with 13 years of NPI registration. Based on federal Medicare data, Dr. John performed 49,048 Medicare services across 2,406 unique beneficiaries.
Between the years covered by Open Payments, Dr. John received a total of $5,416 from 27 pharmaceutical and/or device companies across 155 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. John is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,200 | $43 | $137 |
| Anti-nausea injection (fosaprepitant) | 10,050 | $0 | $5 |
| Nivolumab injection (Opdivo) | 5,820 | $24 | $76 |
| Contrast dye for imaging (iodine-based) | 5,527 | $0 | $3 |
| Paclitaxel chemotherapy injection | 5,496 | $0 | $8 |
| Dexamethasone injection (steroid) | 1,617 | $0 | $1 |
| Injection, lanreotide, 1 mg | 1,560 | $44 | $227 |
| Anti-nausea injection (Aloxi/palonosetron) | 930 | $1 | $114 |
| Immune globulin infusion (Octagam) | 730 | $34 | $235 |
| Injection, granisetron hydrochloride, 100 mcg | 570 | $0 | $24 |
| Comprehensive metabolic blood panel | 412 | $10 | $64 |
| Blood draw (venipuncture) | 410 | $8 | $20 |
| Complete blood count (CBC) with differential | 403 | $8 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 307 | $23 | $157 |
| Office visit, established patient (30-39 min) | 307 | $85 | $368 |
| Administration of chemotherapy into vein, 1 hour or less | 260 | $104 | $707 |
| Injection, leucovorin calcium, per 50 mg | 253 | $3 | $25 |
| Injection of additional new drug or substance into vein | 216 | $12 | $108 |
| Injection, fluorouracil, 500 mg | 197 | $2 | $13 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 192 | $85 | $1,348 |
| Injection, carboplatin, 50 mg | 157 | $2 | $300 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 150 | $3 | $373 |
| Office visit, established patient, complex (40-54 min) | 144 | $134 | $496 |
| Injection, magnesium sulfate, per 500 mg | 96 | $1 | $6 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 93 | $20 | $128 |
| Injection, zoledronic acid, 1 mg | 88 | $7 | $431 |
| Injection, diphenhydramine hcl, up to 50 mg | 81 | $1 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 71 | $50 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $50 | $313 |
| Unclassified drugs | 55 | $1 | $8 |
| Ct scan of chest with contrast | 53 | $49 | $821 |
| Infusion, normal saline solution , 1000 cc | 51 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast | 48 | $179 | $1,067 |
| Administration of chemotherapy into vein, each additional hour | 48 | $23 | $161 |
| Drug injection, under skin or into muscle | 41 | $11 | $96 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 40 | $58 | $211 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 34 | $91 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 33 | $1,183 | $4,802 |
| Infusion into a vein for hydration, each additional hour | 27 | $10 | $75 |
| Hospital follow-up visit, high complexity | 25 | $94 | $357 |
| Blood creatinine level | 22 | $5 | $31 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 21 | $135 | $500 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $16 | $100 |
| New patient office visit, complex (60-74 min) | 20 | $165 | $709 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 19 | $16 | $94 |
| Carcinoembryonic antigen (cea) protein level | 18 | $19 | $99 |
| Administration of chemotherapy into vein using push technique | 17 | $81 | $500 |
| Administration of additional new drug or substance into vein using push technique | 16 | $44 | $289 |
| CT scan of chest, without contrast | 14 | $44 | $686 |
| Application of on-body injector for under skin injection | 14 | $15 | $96 |
| Calcium level, total | 13 | $5 | $30 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (47%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. John is a mixed practice specialist, with above-average Medicare volume (top 21% in TX), with mixed engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. John experienced with pembrolizumab injection (keytruda)?
Does Dr. John receive payments from pharmaceutical companies?
How do Dr. John's costs compare to other medical oncologists in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology